咨詢熱線
15000266580
15000266580
當(dāng)前位置：首頁 >產(chǎn)品中心>細(xì)胞庫>人腫瘤細(xì)胞、癌細(xì)胞>CRL-2557Panc 05.04 人胰腺癌細(xì)胞
簡要描述：CRL-2557 Panc 05.04 人胰腺癌細(xì)胞，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻和培養(yǎng)條件！
產(chǎn)品型號：CRL-2557廠商性質(zhì)：生產(chǎn)廠家 更新時間：2025-04-26訪 問 量：1958 產(chǎn)品分類
Product Category詳細(xì)介紹
CRL-2557 Panc 05.04 人胰腺癌細(xì)胞
ATCC® Number: CRL-2557™ Price: $417.00
Designations: Panc 05.04
Depositors: EM Jaffee
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens （human）
Morphology: epithelial
Source: Organ: pancreas
Disease: adenocarcinoma
Cellular Products: cytokeratins 7 and 18 [50655]
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
CRL-2557 Panc 05.04 人胰腺癌細(xì)胞
Isolation: Isolation date: May 5, 1995
Tumorigenic: Yes
Oncogene: K-ras +
Antigen Expression: MHC class I +; MHC class II - [50655]
Blood type B; Rh+
Age: 77 years adult
Gender: female
Ethnicity: White
Comments: Panc 05.04 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma.
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655]
The cells have a reported plating efficiency of 100%. [50655]
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 20 Units/ml human recombinant insulin, 85%; fetal bovine serum, 15%
Atmosphere: air, 95%; carbon dioxide （CO2）, 5%
Temperature: 37.0°C
Subculturing: Protocol:
1.Remove and discard culture medium.
2.Briefly rinse the cell layer with 0.25% （w/v） Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed （usually within 5 to 15 minutes）.
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5.To remove trypsin-EDTA solution, transfer cell suspension to centrifuge tube and spin at approximay 125 xg for 5 to 10 minutes.Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels.
6.Incubate cultures at 37°C.
Subc*tion Ratio: A subc*tion ratio of 1:3 to 1:5 is recommended
Medium Renewal: Add media once per week. Fluid change one to two times per week.
Preservation: Freeze medium: Complete growth medium supplemented with 5% （v/v） DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 46 hrs
Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001
recommended serum:ATCC 30-2020
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
CRL-2557
產(chǎn)品咨詢
郵箱：xiangfbio@163.com
地址：上海市虹口區(qū)四平路710號7層
掃一掃 微信咨詢